The company has secured $410m in an oversubscribed Series A funding round, co-led by Forbion and General Atlantic, with contributions from investors such as RA Capital Management, OrbiMed ...

Forbion and General Atlantic led the financing, with participation from RA Capital Management, OrbiMed, Logos Capital ... the same GLP-1 class as Novo’s Wegovy and Lilly’s Zepbound that ...

London-based Verdiva Bio has launched with $411 million in series A funding, becoming the latest biotechnology firm to seek weight-loss drug opportunities. The start-up expects to advance its lead ...

The company has secured $410m in an oversubscribed Series A funding round, co-led by Forbion and General Atlantic, with contributions from investors such as RA Capital Management, OrbiMed, Logos ...

Now, a new study finds that Ozempic, along with similar drugs such as Wegovy, has had a broad “economic and societal impact” because of “noticeable shifts in dietary behavior.” The study ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

"What this does is it takes away that signal. It is a miracle drug." GLP-1 agonist drugs, like Ozempic, Wegovy, Mounjaro and Zepbound, can help with weight loss by mimicking at least one ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...